Dupilumab‐associated ocular surface disease is characterized by a shift from Th2/Th17 toward Th1/Th17 inflammation
Allergy2024Vol. 79(4), pp. 937–948
Citations Over TimeTop 1% of 2024 papers
Kathrin Thormann, Anne‐Sophie Lüthi, Felix Deniau, Anja Heider, Simone Cazzaniga, Susanne Radonjic‐Hoesli, Mathias Lehmann, Christoph Schlapbach, Elio L. Herzog, Marco Kreuzer, Martin S. Zinkernagel, Cezmi A. Akdiş, Denise C. Zysset‐Burri, Hans‐Uwe Simon, Dagmar Simon
Abstract
DAOSD is characterized by a Th1/Th17 cytokine profile and an upregulation of markers known to promote remodeling and fibrosis. The expression pattern of inflammatory markers in tear fluids at baseline might serve as a prognostic factor for DAOSD.
Related Papers
- Dupilumab, A Monoclonal Antibody for Atopic Dermatitis: A Review of Current Literature.(2016)
- → Dupilumab treatment improves quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a randomized, placebo-controlled clinical trial(2018)4 cited
- → Case report of the dupilumab applying in atopic dermatitis child(2021)1 cited
- → The Use of Dupilumab in Severe Atopic Dermatitis During Pregnancy: A Case Report(2021)1 cited
- → A Systemic Review of Dupilumab Efficacy and Safety by Phenotypic Variations of Atopic Dermatitis(2021)